

MYC

The MYC family of proto-oncogenes encodes for three MYC oncoproteins: c-MYC, N-MYC and L-MYC.^{1,2} c-MYC is ubiquitous in both fetal and adult proliferating cells, while N- and L-MYC are more limited. These proteins are transcription factors that activate a large number of genes – 15% of all genes are believed to be regulated by MYC proteins.³ Cellular processes that are regulated by MYC include cell cycle, apoptosis, cell growth, differentiation, and metabolism.^{4,5} Because of its importance in these areas, >50% of solid tumors and leukemia feature deregulated MYC^{6,7} and is, thus, an area of intense therapeutic interest.⁸

BI 2536

BI 2536 is a dual Plk/BRD4 inhibitor that destabilizes MYC via inhibiting the deactivation of ubiquitin E3 ligase Fbw7 by Plk1.⁹

Product No: 10-4121 5 mg/ 25 mg/

P22077

An inhibitor of USP7 (HAUSP) that destabilizes N-MYC protein levels in a panel of neuroblastoma cell lines.¹⁰

Product No: 10-4125 10 mg/ 50 mg/

Rapamycin

Rapamycin limited expression of c-MYC in granulocytes by inhibiting c-MYC mRNA translation.¹¹

Product No: 10-1104 10 mg/ 50 mg/

MK-2206

MK2206 is a potent and highly specific allosteric pan-Akt inhibitor. Akt has been shown to act synergistically with c-MYC to activate tRNA synthesis and ribosome biogenesis in lymphomas.^{12,13}

Product No: 10-4801 5 mg/ 25 mg/

10058-F4

10058-F4 disables c-MYC by inhibiting formation of the c-MYC-MAX complex.¹⁴

Product No: 10-1466 5 mg/ 25 mg/

JQ1

BET bromodomain inhibitor that selectively downregulates MYC and MYC-dependent target genes.¹⁵

Product No: 10-1361 5 mg/ 25 mg/

THZ1

THZ1 is a potent covalent inhibitor of CDK7 that decreases STAT3 chromatin binding and MYC expression.¹⁶

Product No: 10-4120 5 mg/ 25 mg/

Stauprimide

Stauprimide selectively suppresses MYC transcription in a variety of cancer cell *in vitro* and inhibits tumor growth in mouse models.¹⁷

Product No: 10-1189 1 mg/ 5 mg/

Alisertib

Alisertib is a potent and selective inhibitor of Aurora A kinase (AurA). It disrupts the AurA/N-MYC complex leading to destabilization of N-MYC.¹⁸

Product No: 10-4124 5 mg/ 25 mg/

10074-G5


Inhibits c-Myc by disrupting c-Myc/Max heterodimer formation and inhibiting its transcriptional activity.¹⁹

Product No: 10-5627 5 mg/ 25 mg/


I-BET762

BET bromodomain inhibitor that downregulates Myc transcription.²⁰

Product No: 10-4122 5 mg/ 25 mg/



BI 2536



Alisertib

REFERENCES

1. Adhikary and Eilers (2005), *Nat.Rev.Mol.Cell Biol.* **6** 635
2. Dang (2012), *Cell* **149** 22
3. Dang *et al.* (2006), *Semin.Cancer Biol.* **16** 253
4. Bretones *et al.* (2015), *Biochim.Biophys. Acta* **1849** 506
5. Miller *et al.* (2012), *Clin.Cancer Res.* **18** 5546
6. Vita and Hendriksson (2006), *Semin.Cancer Biol.* **16** 318
7. Delgado and Leon (2010), *Genes Cancer* **1** 605
8. Chen *et al.* (2018), *Signal Transduct.Target Ther.* **3** 5
9. Xiao *et al.* (2016). *Mol.Cell* **64** 493
10. Tavana *et al.* (2016) *Nat.Med.* **22** 1180
11. Wall *et al.* (2008). *Blood* **112** 2305
12. Chan *et al.* (2011), *Sci.Signal.* **4** ra56
13. Devlin *et al.* (2013), *FEBS J.* **280** 5307
14. Yin *et al.* (2003), *Oncogene* **22** 6151
15. Delmore *et al.* (2011), *Cell* **146** 904
16. Cayrol *et al.* (2017), *Nat. Commun.* **8** 14290
17. Bouvard *et al.* (2017), *PNAS* **114** 3497
18. Richards *et al.* (2016), *PNAS* **113** 13726
19. Follis *et al.* (2008), *Chem. Biol.* **15** 1149
20. Delmore *et al.* (2011), *Cell* **146** 904